What Z19 covers · when clinicians use it
ICD-10 code Z19 identifies Hormone sensitivity malignancy status in the U.S. ICD-10-CM clinical and billing record set. It sits within the Factors Influencing Health Status chapter (Z00–Z99), the section that groups related diagnoses so providers, payers, and public-health agencies report them consistently. Clinicians and medical coders apply Z19 when an encounter's findings match the Hormone sensitivity malignancy status description, attaching it to the patient record so downstream insurance claims, payer audits, quality reporting, and epidemiological surveillance all reference the same standardized diagnosis. The ICD-10-CM is maintained by the Centers for Medicare & Medicaid Services and the CDC's National Center for Health Statistics, with an updated official code set released each U.S. fiscal year — always verify Z19 against the current CMS/CDC release and your payer's documentation guidance before final use. This page summarizes documentation context for Z19 and is a coding reference, not clinical, diagnostic, or billing advice.
Hormone sensitivity malignancy status (Z19) captures important diagnostic findings that influence patient management, such as antimicrobial drug resistance, hormonal receptor statuses, presence of retained foreign bodies, and hormone sensitivity of malignancies. These findings guide therapeutic decisions and clinical outcomes.
Symptoms
- Infections not responding to antibiotics (Z16)
- Breast cancer or other tumors assessed for hormone receptor positivity (Z17, Z19)
- Chronic pain or inflammation from retained surgical fragments (Z18)
- Treatment failure in antimicrobial therapies
- Diagnostic challenges in oncologic or infectious disease cases
- Need for tailored therapeutic approaches based on receptor or resistance status
Diagnosis
Diagnosis involves laboratory cultures and susceptibility testing for resistance (Z16), biopsy and immunohistochemistry for receptor statuses (Z17, Z19), and imaging techniques (X-rays, CT scans, ultrasound) to detect retained foreign objects (Z18). These findings often directly impact treatment plans.
ICD10 Code Usage
The ICD10 code Z19 is used in medical records, oncology and infectious disease registries, insurance claims, research databases, and hospital quality reporting systems. Proper coding supports personalized medicine initiatives, antibiotic stewardship programs, surgical quality improvement, and cancer therapy optimization.
Related Codes
- Z16 – Resistance to antimicrobial drugs
- Z17 – Estrogen, and other hormones and factors receptor status
- Z18 – Retained foreign body fragments
FAQs
Q1: What does ICD10 code Z19 classify?
A: It documents diagnostic findings like antibiotic resistance (Z16), hormonal receptor status (Z17), retained foreign body fragments (Z18), or hormone sensitivity of cancers (Z19).
Q2: Why is antibiotic resistance coding important?
A: It helps track resistance patterns, guide antibiotic selection, and inform public health antimicrobial stewardship initiatives.
Q3: How does receptor status influence cancer treatment?
A: Hormone receptor positivity in cancers like breast cancer affects eligibility for targeted hormonal therapies.
Q4: Can retained surgical fragments cause complications?
A: Yes, they may cause infection, inflammation, pain, or delayed healing, sometimes requiring removal.
Q5: How do these codes improve healthcare?
A: They enable better tracking of critical clinical findings, personalize treatment strategies, and support healthcare quality improvements.
Conclusion
Using ICD10 code Z19 for Hormone sensitivity malignancy status ensures accurate capture of important diagnostic findings, leading to personalized medical care, improved patient outcomes, and better public health monitoring and clinical research initiatives.